secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001867096-24-000183
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Q3 total revenue $54.3M record; guides FY to $198-$202M
-------------------------------------------------------------

- Product revenue $52.9M (+27% YoY); Gvoke $22.9M (+29%), Recorlev $17.7M (+119%), Keveyis $12.2M (-23%).
- Net loss $15.7M ($0.11 EPS); excludes CEO succession restructuring costs of $6.1M gives adjusted EPS ($0.06).
- FY 2024 total net revenue guidance raised to $198-202M from prior $190-200M; year-end cash guided to $68-72M.
- Cash, cash equivalents and short-term investments $69.4M at Sept 30, 2024.
- 12th consecutive quarter of product revenue growth >20%; Recorlev patient count +125% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000183/0001867096-24-000183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000183/xers-20241108.htm
  HTML page:      https://secwatch.observer/filing/0001867096-24-000183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer